DEDICATED NUCLEAR MEDICINE BREAST IMAGING DEVICE

专用核医学乳腺成像设备

• 批准号: 2109887
• 负责人: GERD MUEHLLEHNER
• 金额: $ 8.04万
• 依托单位: UGM LABORATORY, INC.
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-03-10 至 1995-09-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2109887
• 关键词: biomedical equipment development; breast neoplasm /cancer diagnosis; deoxyglucose; iodine; method development; neoplasm /cancer radionuclide diagnosis; nuclear medicine; positron emission tomography; radiation detector; radiotracer; single photon emission computed tomography; technetium; thallium

Currently, mammography is an important tool in breast cancer screening and has been shown to reduce mortality by early detection. Despite being a very sensitive technique, mammography's specificity is limited in that only approximately 10-30% of mammographically-directed biopsies are positive. Both PET and single-photon Nuclear Medicine imaging studies using Thallium-201, Technetium-99m Sestamibi, and F-18 Fluorodeoxyglucose have been shown to provide sensitive and specific detection of breast cancers. Nuclear Medicine studies would provide cost-effective methods for Secondary breast cancer screening by limiting the number of negative biopsies. For this Purpose, we propose a dedicated Nuclear Medicine breast imaging device based on NaI(T1) detectors capable of performing both PET and single-photon studies. Since both PET and single-photon radiotracers are likely to play a role in breast cancer detection, a device capable of imaging both tracers is ideally suited to the task. Besides improving the quality of breast imaging over current instrumentation, this device should be sufficiently inexpensive to make Nuclear Medicine breast cancer imaging cost-effective as a secondary Screening method. In this Phase I application, we propose to study the feasibility of this device and begin its overall design.

目前，乳房X线摄影是乳腺癌筛查的重要工具。 已被证明可以通过早期发现降低死亡率。尽管是一个 非常敏感的技术，乳房X线照相术的特异性有限 只有约 10-30% 的乳腺 X 线定向活检是 积极的。 PET 和单光子核医学成像研究 使用 Thallium-201、Technetium-99m Sestamibi 和 F-18 氟脱氧葡萄糖 已被证明可以提供灵敏且特异的乳房检测 癌症。核医学研究将为以下方面提供具有成本效益的方法： 通过限制阴性数量进行二次乳腺癌筛查 活检。为此，我们提出了专门的核医学乳房 基于 NaI(T1) 探测器的成像装置能够执行 PET 和单光子研究。 由于 PET 和单光子放射性示踪剂 可能在乳腺癌检测中发挥作用，这是一种能够 对两种示踪剂进行成像非常适合这项任务。除了改善 与当前仪器相比，该设备的乳腺成像质量应该 足够便宜来进行核医学乳腺癌成像 作为二次筛选方法具有成本效益。在这个第一阶段 应用，我们建议研究该设备的可行性并开始 它的整体设计。